Philippe JEAN-PIERRE

---

• Type de publi. : Communication dans un congrès
• Date de publi. : 31/08/2021
• Auteurs : Christophe BernardPierre-Jean BouvetAntony PottierPhilippe Forjonel
• Organismes : Systèmes Embarqués, Acoustique et Télécommunications Systèmes Embarqués, Acoustique et Télécommunications Systèmes Embarqués, Acoustique et Télécommunications Systèmes Embarqués, Acoustique et Télécommunications

---

Résumé : This article presents a new multiple access technique for underwater acoustic communication in the framework of autonomous underwater vehicle fleet. The multiuser scheme is based on a set of orthogonal waveforms built by combining 2 types of HFM signals allowing at the reception side very simple matched filter based decoding. The proposed multiuser technique provides good resilience against multiuser interference while keeping robustness against underwater acoustic channel impairments like Doppler shift. The implementation of this protocol for the underwater acoustic scenario is described, and performance are analysed and compared against conventional TDMA and CDMA techniques over replayed experimental channels. Index Terms-Underwater acoustic communication; code division multiple access (CDMA); time division multiple access (TDMA).

---

Fichiers liés : multiple_access_acomm_in_underwater_mobile_networks.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/08/2021
• Auteurs : Frédéric AnselmeArnaud SavouréNicolas ClémentyOlivier CesariDominique PavinLaurence JeselPascal DefayeSerge BovedaPhilippe RivatJacques MansouratiAlexis MechulanJean‐pierre CebronGilles LandeMichael Bubenheim ScdAntoine Milhem
• Organismes : Nanomédecine Régénérative Hôpital de la Cavale Blanche - CHRU Brest Optimisation des régulations physiologiques
• Publié dans Journal of Arrhythmia le 05/10/2021

---

Résumé : Background Although less common, typical atrial flutter shares similar pathophysiological roots with atrial fibrillation. Following successful cavo-tricuspid isthmus ablation using radiofrequency, many patients, however, develop atrial fibrillation in the mid-to-long-term. This study sought to assess whether pulmonary vein isolation conducted at the same time as cavo-tricuspid isthmus ablation would significantly modify the atrial fibrillation burden upon follow-up in patients suffering from typical atrial flutter. Methods This was a multicenter randomized controlled study involving typical atrial flutter patients with history of non-predominant atrial fibrillation (1 atrial fibrillation episode only, in 67% of population) who were scheduled for cavo-tricuspid isthmus radiofrequency ablation. Patients were randomly assigned to either undergo cavo-tricuspid isthmus ablation alone or cavo-tricuspid isthmus plus pulmonary vein isolation (CTI+). Pulmonary vein isolation was performed using cryoballoon technology. An outpatient consultation with ECG and 1-week Holter monitoring was performed at 3, 6 months, 1 year, and 2 years postprocedure. The primary endpoint was atrial fibrillation recurrences lasting more than 30 s at 2 years postablation. Results Of the patients enrolled, 36 were included in each group. At 2-year follow-up, the atrial fibrillation recurrence rate was significantly higher in the CTI vs CTI+group (25/36, 69% vs. 12/36, 33% respectively; P < .001), with similar typical atrial flutter recurrence rates. There were no differences in undesirable events, except for transient phrenic nerve palsy reported from three CTI+patients (8.3%). Conclusion Pulmonary vein isolation using cryoballoon technology was proven to significantly reduce the atrial fibrillation incidence at 2 years postcavo-tricuspid isthmus ablation. .

---

Fichiers liés : Journal of Arrhythmia - 2021 - Anselme - Preventing atrial fibrillation by combined right isthmus ablation and cryoballoon.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 28/08/2021
• Auteurs : Jean-Yves DouetAlvina HuorHervé CassardSéverine LuganNaïma AronChloé MesicDidier ViletteTomás BarrioNathalie StreichenbergerArmand Perret-LiaudetMarie-Bernadette DelislePatrice PéranJean-Philippe DeslysEmmanuel ComoyJean-Luc VilotteKatayoun GoudarziVincent BéringueMarcelo A. BarriaDiane L. RitchieJames W. IronsideOlivier Andréoletti
• Organismes : Interactions hôtes-agents pathogènes [Toulouse] Interactions hôtes-agents pathogènes [Toulouse] Interactions hôtes-agents pathogènes [Toulouse] Interactions hôtes-agents pathogènes [Toulouse] Interactions hôtes-agents pathogènes [Toulouse] Interactions hôtes-agents pathogènes [Toulouse] Interactions hôtes-agents pathogènes [Toulouse] Interactions hôtes-agents pathogènes [Toulouse] Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Hospices Civils de Lyon Centre de recherche en neurosciences de Lyon - Lyon Neuroscience Research Center Hospices Civils de Lyon Toulouse NeuroImaging Center Toulouse NeuroImaging Center CEA- Saclay CEA- Saclay Génétique Animale et Biologie Intégrative Génétique Animale et Biologie Intégrative Virologie et Immunologie Moléculaires The University of Edinburgh The University of Edinburgh The University of Edinburgh Interactions hôtes-agents pathogènes [Toulouse]
• Publié dans Acta Neuropathologica Communications le 01/11/2020

---

Résumé : Treatment with human pituitary-derived growth hormone (hGH) was responsible for a significant proportion of iatrogenic Creutzfeldt–Jakob disease (iCJD) cases. France and the UK experienced the largest case numbers of hGH-iCJD, with 122 and 81 cases respectively. Differences in the frequency of the three PRNP codon 129 polymorphisms (MM, MV and VV) and the estimated incubation periods associated with each of these genotypes in the French and the UK hGH-iCJD cohorts led to the suggestion that the prion strains responsible for these two hGH-iCJD cohorts were different. In this study, we characterized the prion strains responsible for hGH-iCJD cases originating from UK (n = 11) and France (n = 11) using human PrP expressing mouse models. The cases included PRNP MM, MV and VV genotypes from both countries. UK and French sporadic CJD (sCJD) cases were included as controls. The prion strains identified following inoculation with hGH-iCJD homogenates corresponded to the two most frequently observed sCJD prion strains (M1 CJD and V2 CJD ). However, in clear contradiction to the initial hypothesis, the prion strains that were identified in the UK and the French hGH-iCJD cases were not radically different. In the vast majority of the cases originating from both countries, the V2 CJD strain or a mixture of M1 CJD + V2 CJD strains were identified. These data strongly support the contention that the differences in the epidemiological and genetic profiles observed in the UK and France hGH-iCJD cohorts cannot be attributed only to the transmission of different prion strains.

---

Fichiers liés : s40478-021-01247-x.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 26/08/2021
• Auteurs : Nathalie FeuilletStephan JorryWayne C. CrawfordChristine DeplusIsabelle ThinonEric JacquesJean-Marie SaurelAnne LemoineFabien PaquetClaudio SatrianoChastity AikenOcéane FoixPhilippe KowalskiAngèle LaurentEmmanuel RinnertCécile CathalotJean-Pierre DonvalVivien GuyaderArnaud GaillotCarla ScalabrinManuel MoreiraAline PeltierFrançois BeauducelRaphael GrandinValérie BalluRomuald DanielPascal PelleauJérémy GomezSimon BesançonLouis GeliPascal BernardPatrick BacheleryYves FouquetDidier BertilArnaud LemarchandJerome van Der Woerd
• Organismes : Institut de Physique du Globe de Paris Institut Français de Recherche pour l'Exploitation de la Mer Institut de Physique du Globe de Paris Institut de Physique du Globe de Paris Bureau de Recherches Géologiques et Minières Institut de Physique du Globe de Paris Institut de Physique du Globe de Paris Bureau de Recherches Géologiques et Minières Bureau de Recherches Géologiques et Minières Institut de Physique du Globe de Paris Institut Français de Recherche pour l'Exploitation de la Mer Institut de Physique du Globe de Paris Institut de Physique du Globe de Paris Institut de Physique du Globe de Paris Institut Français de Recherche pour l'Exploitation de la Mer Institut Français de Recherche pour l'Exploitation de la Mer Institut Français de Recherche pour l'Exploitation de la Mer Institut Français de Recherche pour l'Exploitation de la Mer Institut Français de Recherche pour l'Exploitation de la Mer Institut Français de Recherche pour l'Exploitation de la Mer Institut de Physique du Globe de Paris Institut de Physique du Globe de Paris Institut de Physique du Globe de Paris Institut de Physique du Globe de Paris LIttoral ENvironnement et Sociétés Institut de Physique du Globe de Paris Institut Français de Recherche pour l'Exploitation de la Mer Institut de Physique du Globe de Paris Institut de Physique du Globe de Paris Institut Français de Recherche pour l'Exploitation de la Mer Institut de Physique du Globe de Paris Observatoire de Physique du Globe de Clermont-Ferrand Institut Français de Recherche pour l'Exploitation de la Mer Bureau de Recherches Géologiques et Minières Institut de Physique du Globe de Paris Institut Terre Environnement Strasbourg
• Publié dans Nature Geoscience le 26/10/2020

---

Résumé : Volcanic eruptions shape the Earth's surface and provide a window into deep Earth processes. How the primary asthenospheric melts form, pond and ascend through the lithosphere is, however, still poorly understood. Since 10 May 2018, magmatic activity has occurred offshore eastern Mayotte (North Mozambique channel), associated with large surface displacements, very low frequency earthquakes and exceptionally deep earthquake swarms. Here we present geophysical and marine data from the MAYOBS1 cruise, which reveal that by May 2019, this activity formed a 820 m tall, ~5 km³ volcanic edifice on the seafloor. This is the largest active submarine eruption ever documented. Seismic and deformation data indicate that deep (> 55 km depth) magma reservoirs were rapidly drained through dykes that intruded the entire lithosphere, and that preexisting subvertical faults in the mantle were reactivated beneath an ancient caldera

---

Fichiers liés : feuilletetal-copie-CRAC.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 24/08/2021
• Auteurs : Servane Gay-ChevallierLouis de MestierJulie PerinelJulien ForestierValérie HervieuPhilippe RuszniewskiIngrid MillotPierre-Jean ValetteMathieu PiocheCatherine Lombard-BohasFabien SubtilMustapha AdhamThomas Walter
• Organismes : Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 Service de Biostatistiques [Lyon] Hospices Civils de Lyon
• Publié dans Neuroendocrinology le 31/10/2020

---

Résumé : Introduction: The characteristics, prognostic factors, and management of duodenal neuroendocrine neoplasms (dNEN) are ill-defined, given their rarity. Whether nonsurgical management might be appropriate for patients with nonmetastatic dNEN and a good prognosis, as is the case for pancreatic NEN (pNEN), is unknown. We aimed to describe the management and prognosis of nonmetastatic dNEN patients. Methods: All consecutive patients with nonmetastatic dNEN managed between 1981 and 2018 in 2 expert centers were included. Recurrence-free survival (RFS) and factors associated with recurrence were estimated. Results: A total of 145 patients with dNEN were included. Twenty-eight patients with sporadic, nonfunctioning, small (median 7 mm) dNEN underwent endoscopic resection, with a 5-year RFS rate of 89.4%. Local recurrence occurred in 2 patients, who underwent surgery with no new events. The 5-year RFS rate was 87.9% in patients who underwent surgery. Upon univariate analysis, age, size, Ki67 index, and lymph node involvement (LN+) were significantly associated with worse RFS for all dNEN treated (endoscopy/surgery); multivariate analysis found that age, size, and LN+ were associated with worse RFS. Conclusion: Selected nonmetastatic dNEN had a favorable outcome, and a less invasive therapeutic strategy appeared more suitable than oncological surgery.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 24/08/2021
• Auteurs : Marianne VeyriArmelle LavoléSylvain ChoquetDominique CostagliolaCaroline SolasChristine KatlamaIsabelle Poizot-MartinJean-Philippe Spano
• Organismes : Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Tenon [AP-HP] CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Hôpital de la Timone [CHU - APHM] CHU Pitié-Salpêtrière [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique Rhumatologie [Sainte- Marguerite - APHM] Institut Pierre Louis d'Epidémiologie et de Santé Publique
• Publié dans Bulletin du Cancer le 01/11/2020

---

Résumé : Introduction People living with HIV (PLWHIV) are at a higher risk of cancer compared to the general population. With improved cancer treatments and the increased life expectancy of PLWHIV, the incidence of second cancers is also expected to increase. Methods We reviewed the cases of PLWHIV with cancer that have been presented to the CANCERVIH national multidisciplinary board since 2014. We included all cases with a history of cancer, and studied the incidence and types of second cancers. Results In total, 719 cases were reviewed, out of which 94 (13%) had a history of at least one cancer. For the first primary cancers, 46 (49%) were AIDS-defining cancers (ADCs) and 48 (51%) were non-AIDS-defining cancers (NADCs). Kaposi sarcoma (33%) and NHL (15%) occurred most frequently as first cancers. Among the first cancers that were ADCs, 15% of the second cancers were NHL, 11% anal canal cancers, 9% bladder and 9% Hodgkin lymphomas. Among the first cancers that were NADCs, 38% of the second cancers were lung cancers, 8% bladder, 8% head and neck and 8% NHL. Discussion With the aging of PLWHIV, the incidence of second and subsequent cancers is expected to increase in this population. Immuno-virological control should be maintained. Increased surveillance, early prevention and screening programs should be offered to all PLWHIV, including those with an undetectable HIV viral load and/or immune restoration.

---

Fichiers liés : Article PLWHIV secondary cancers (accepted).pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 23/08/2021
• Auteurs : Francisco Sáez-OrellanaThomas LeroyFloriane RibeiroAnna KreisKarelle LeroyFanny LalloyerEric BaugéBart StaelsCharles DuyckaertsJean-Pierre BrionPhilippe GaillyJean-Noël OctaveNathalie Pierrot
• Organismes : Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011 Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U 1011
• Publié dans JCI Insight le 27/10/2020

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 21/08/2021
• Auteurs : Boris JungClément Le BihanPierre PortalesNathalie BourgeoisThierry VincentLaurence LachaudGerald ChanquesMatthieu ConseilPhilippe CornePablo MassanetJean François TimsitSamir Jaber
• Organismes : Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle Centre Hospitalier Régional Universitaire [Montpellier] Institut des Neurosciences de Montpellier Centre Hospitalier Régional Universitaire [Montpellier] Maladies infectieuses et vecteurs : écologie, génétique, évolution et contrôle Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Régional Universitaire [Montpellier] Centre Hospitalier Universitaire de Nîmes CIC - CHU Bichat Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier]
• Publié dans Annals of Intensive Care le 23/10/2020

---

Résumé : Background Precision medicine risk stratification is desperately needed to both avoid systemic antifungals treatment delay and over prescription in the critically ill with risk factors. The aim of the present study was to explore the combination of host immunoparalysis biomarker (monocyte human leukocyte antigen-DR expression (mHLA-DR)) and Candida sp wall biomarker β- d -glucan in risk stratifying patients for secondary invasive Candida infection (IC). Methods Prospective observational study. Two intensive care units (ICU). All consecutive non-immunocompromised septic shock patients. Serial blood samples ( n = 286) were collected at day 0, 2 and 7 and mHLA-DR and β- d -glucan were then retrospectively assayed after discharge. Secondary invasive Candida sp infection occurrence was then followed at clinicians’ discretion. Results Fifty patients were included, 42 (84%) had a Candida score equal or greater than 3 and 10 patients developed a secondary invasive Candida sp infection. ICU admission mHLA-DR expression and β- d -glucan (BDG) failed to predict secondary invasive Candida sp infection. Time-dependent cause-specific hazard ratio of IC was 6.56 [1.24–34.61] for mHLA-DR < 5000 Ab/c and 5.25 [0.47–58.9] for BDG > 350 pg/mL. Predictive negative value of mHLA-DR > 5000 Ab/c and BDG > 350 pg/mL combination at day 7 was 81% [95% CI 70–92]. Conclusions This study suggests that mHLA-DR may help predicting IC in high-risk patients with septic shock. The added value of BDG and other fungal tests should be regarded according to the host immune function markers.

---

Fichiers liés : s13613-021-00918-1.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 21/08/2021
• Auteurs : Raphael Romano BrunoBernhard WernlyHans FlaattenJesper FjølnerAntonio ArtigasBernardo Bollen PintoJoerg C SchefoldStephan BinnebösselPhilipp Heinrich BaldiaMalte KelmMichael BeilSivri SigalPeter Vernon Van HeerdenWojciech SzczeklikMuhammed ElhadiMichael JoannidisSandra OeyenTilemachos ZafeiridisJakob WollbornMaria José Arche BanzoKristina FuestBrian MarshFinn H AndersenRui MorenoSusannah LeaverAriane BoumendilDylan W De LangeBertrand GuidetChristian JungPhilipp EllerMichael JoannidisDieter MesottenPascal ReperSandra OeyenWalter SwinnenNicolas SerckElisabeth DewaeleEdwin ChapetaHelene BrixJens BrushoejPritpal KumarHelene Korvenius NedergaardTim Koch JohnsenCamilla BundesenMaria Aagaard HansenStine UhrenholtHelle BundgaardJesper FjølnerRichard InnesJames GoochLenka CagovaElizabeth PotterMichael ReayMiriam DaveyMohammed Abdelshafy AbusayedSally HumphreysAmy CollinsAvinash AujayebSusannah LeaverWaqas KhaliqAyman Abdelmawgoad HabibMohammed A AzabKyrillos WassimYumna A ElgazzarRehab SalahHazem Maarouf AbosheaishaaAliae a R Hussein MohamedAhmed Y AzzamSamar TharwatYasmin Khairy Nasreldin Mohamed AliOmar ElmandouhIslam GalalAhmed Abu-ElfatthKaram MotaweaMohammad ElbahnasawyMostafa ShehataMohamed ElbahnasawyMostafa TayebNermin OsmanWafaa Abdel-ElsalamAliae Mohamed HusseinAmer AldhaliaArnaud GalboisBertrand GuidetCyril CharronCaroline Hauw BerlemontGuillaume BeschJean-Philippe RigaudJulien MaizelMichel DjibréPhilippe BurtinPierre GarconSaad NseirXavier ValetteNica AlexandruNathalie MarinMarie VaissiereGaëtan PlantefeveHervé MentecThierry VanderlindenIgor JurcisinBuno MegarbaneBenjamin ChoustermanFrançois DépretMarc GarnierSebastien BessetJohanna OzielAlexis FerreStéphane DaugerGuillaume DumasBruno GoncalvesLucie VettorettiDidier TheveninStefan SchallerMuhammed KurtAndreas FaltlhauserChristian MeyerMilena MilovanovicMatthias LutzGonxhe ShalaHendrik HaakeWinfried RanderathAnselm KunsteinPatrick MeybohmStephan SteinerEberhard BarthTudor PoernerPhilipp SimonMarco LorenzZouhir DindaneKarl Friedrich KuhnMartin WelteIngo VoigtHans-Joachim KabitzJakob WollbornUlrich GoebelSandra Emily StollDetlef Kindgen-MillesSimon DublerChristian JungKristina FuestMichael SchusterStephan SteinerAntonios PapadogoulasFrancesk MulitaNikoletta RovinaZoi AidoniEvangelia ChrisanthopoulouEumorfia KondiliIoannis AndrianopoulosMohan GurjarAta MahmoodpoorRand HusseinMaytham Aqeel Al-JuaifariAbdullah Khudhur Ahmed KarantenachySigal SviriAhmed ElsakaBrian MarshVittoria ComelliniFarah Al-AliSari AlmaniAlmu' Atasim KhameesKhayry Al-ShamiIbrahim Salah El DinTaha AbubakerHazem AhmedAhmed RabhaAbdulmueti AlhadiMarwa EmhamedSaedah AbdeewiAbdurraouf AbusalamaAbdulmueti AlhadiMohammed HuwayshEsraa Abdalqader AlghatiAbdelilah GhannamSilvio A Namendys-SylvaMartijn GroenendijkMirjam EversLenneke Van Lelyveld-HaasIwan MeynaarAlexander Daniel CornetMarieke ZegersWillem DieperinkDylan De LangeTom DormansMichael HahnBritt SjøbøeHans Frank StrietzelTheresa OlasveengenLuis RomundstadFinn H AndersenJohn George Grace MassoudAamir Ghafoor KhanShahd Al-QasrawiSarah AmroAnna KluzikPaweł ZatorskiTomasz DrygalskiWojciech SzczeklikJakub KlimkiewiczJoanna Solek-PastuszkaDariusz OnichimowskiMiroslaw CzuczwarRyszard GawdaJan StefaniakKarina Stefanska-WronkaEwa ZabulAna Isabel Pinho OliveiraRui AssisMaria de Lurdes Campos SantosHenrique SantosFilipe Sousa CardosoAndré GordinhoIoana Marina GrintescuDana TomescuMohamed Raafat BadawyM José Arche BanzoBegoña Zalba-EtayoPatricia Jimeno CuberoJesús PriegoGemma GomàTeresa Maria Tomasa-IrriguibleSusana SanchoAida Fernández FerreiraEric Mayor VázquezÁngela Prado MiraMercedes IbarzDavid IglesiasSusana Arias-RiveraFernando Frutos-VivarSonia Lopez-CuencaCesar AldecoaDavid Perez-TorresIsabel Canas-PerezLuis Tamayo-LomasCristina Diaz-RodriguezPablo Ruiz De GopeguiMahmoud SalehMomin Majed Yousuf HillesEnas M Y AbualqumbozNawfel Ben-HamoudaAndrea RobertiYvan FleuryNour AbidiJoerg C SchefoldIvan ChauAlexander DullenkopfMohammad Karam ChaabanMohammed Mouaz ShebaniAhmad HmaidehAymen ShaherAyca Sultan SahinKemal Tolga SaracogluMohammed Al-SadawiRichard PughSara SmutsRafat Ameen Mohammed Al-Saban
• Organismes : Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Saint-Antoine [AP-HP] Mécanismes physiopathologiques et conséquences des calcifications cardiovasculaires - UR UPJV 7517
• Publié dans Annals of Intensive Care le 23/10/2020

---

Résumé : Purpose: Lactate is an established prognosticator in critical care. However, there still is insufficient evidence about its role in predicting outcome in COVID-19. This is of particular concern in older patients who have been mostly affected during the initial surge in 2020. Methods: This prospective international observation study (The COVIP study) recruited patients aged 70 years or older (ClinicalTrials.gov ID: NCT04321265) admitted to an intensive care unit (ICU) with COVID-19 disease from March 2020 to February 2021. In addition to serial lactate values (arterial blood gas analysis), we recorded several parameters, including SOFA score, ICU procedures, limitation of care, ICU- and 3-month mortality. A lactate concentration ≥ 2.0 mmol/L on the day of ICU admission (baseline) was defined as abnormal. The primary outcome was ICU-mortality. The secondary outcomes 30-day and 3-month mortality. Results: In total, data from 2860 patients were analyzed. In most patients (68%), serum lactate was lower than 2 mmol/L. Elevated baseline serum lactate was associated with significantly higher ICU- and 3-month mortality (53% vs. 43%, and 71% vs. 57%, respectively, p < 0.001). In the multivariable analysis, the maximum lactate concentration on day 1 was independently associated with ICU mortality (aOR 1.06 95% CI 1.02-1.11; p = 0.007), 30-day mortality (aOR 1.07 95% CI 1.02-1.13; p = 0.005) and 3-month mortality (aOR 1.15 95% CI 1.08-1.24; p < 0.001) after adjustment for age, gender, SOFA score, and frailty. In 826 patients with baseline lactate ≥ 2 mmol/L sufficient data to calculate the difference between maximal levels on days 1 and 2 (∆ serum lactate) were available. A decreasing lactate concentration over time was inversely associated with ICU mortality after multivariate adjustment for SOFA score, age, Clinical Frailty Scale, and gender (aOR 0.60 95% CI 0.42-0.85; p = 0.004). Conclusion: In critically ill old intensive care patients suffering from COVID-19, lactate and its kinetics are valuable tools for outcome prediction.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 14/08/2021
• Auteurs : Vincent CavalRodolphe SuspènePierre KhalfiJulien GaillardGrégory CaignardDamien VitourPhilippe RoingeardJean Pierre VartanianSimon Wain-Hobson
• Organismes : Rétrovirologie Moléculaire Rétrovirologie Moléculaire Rétrovirologie Moléculaire Ecole Doctorale Complexité du Vivant Morphogénèse et antigénicité du VIH, des Virus des Hépatites et Emergents Plateforme IBISA de Microscopie Electronique [CHRU de Tours] Virologie UMR1161 Virologie UMR1161 Morphogénèse et antigénicité du VIH, des Virus des Hépatites et Emergents Plateforme IBISA de Microscopie Electronique [CHRU de Tours] Rétrovirologie Moléculaire Rétrovirologie Moléculaire
• Publié dans Journal of Biological Chemistry le 02/11/2020

---

Résumé : The human APOBEC3A (A3A) cytidine deaminase is a powerful DNA mutator enzyme recognized as a major source of somatic mutations in tumor cell genomes. However, there is a discrepancy between APOBEC3A mRNA levels after interferon stimulation in myeloid cells and A3A detection at the protein level. To understand this difference, we investigated the expression of two novel alternative "A3Alt" proteins encoded in the +1-shifted reading frame of the APOBEC3A gene. A3Alt-L and its shorter isoform A3Alt-S appear to be transmembrane proteins targeted to the mitochondrial compartment that induce membrane depolarization and apoptosis. Thus, the APOBEC3A gene represents a new example wherein a single gene encodes two pro-apoptotic proteins, A3A cytidine deaminases that target the genome and A3Alt proteins that target mitochondria.

---

Fichiers liés : 1-s2.0-S002192582100884X-main.pdf

---

Source